Compare LAZR & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAZR | RZLT |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | 580 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.1M | 187.3M |
| IPO Year | N/A | N/A |
| Metric | LAZR | RZLT |
|---|---|---|
| Price | $0.50 | $1.84 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $1.00 | ★ $12.33 |
| AVG Volume (30 Days) | ★ 54.1M | 13.0M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $75,753,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.97 | N/A |
| 52 Week Low | $0.18 | $1.07 |
| 52 Week High | $10.40 | $11.46 |
| Indicator | LAZR | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 24.57 |
| Support Level | $0.18 | $1.07 |
| Resistance Level | $1.04 | $2.25 |
| Average True Range (ATR) | 0.18 | 0.60 |
| MACD | -0.02 | -0.77 |
| Stochastic Oscillator | 47.22 | 7.13 |
Luminar Technologies Inc is an automotive technology company ushering in a new era of vehicle safety and autonomy. It operates its business through the following segments: Autonomy Solutions and Advanced Technologies and Services. The majority of its revenue is generated from the Autonomy Solutions segment, which engages in the design, manufacturing, and sale of LiDAR sensors, catering mainly to the OEMs in the automobile, commercial vehicle, robo-taxi, and adjacent industries. The Advanced Technologies and Services segment provides semiconductors and related components, as well as design, test, and consulting services to the Autonomy Solutions segment and various third-party customers. Geographically, the company derives its key revenue from North America.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.